Patent application number | Description | Published |
20080220453 | Identification and isolation of squamous carcinoma stem cells - Squamous carcinoma stem cells (SCSC) are identified. The cells can be prospectively isolated or identified from primary tumor samples, and are shown to possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation, and to form unique histological microdomains useful in cancer diagnosis. | 09-11-2008 |
20090191202 | Methods for manipulating phagocytosis mediated by CD47 - Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable. | 07-30-2009 |
20100226927 | SELECTIVE IMMUNODEPLETION OF ENDOGENOUS STEM CELL NICHE FOR ENGRAFTMENT - The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment and tolerance. | 09-09-2010 |
20100267079 | Identification and isolation of transitional cell carcinoma stem cells - Transitional cell carcinoma stem cells (TCCSC) are identified. The cells can be prospectively isolated or identified from primary tumor samples, and are shown to possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation, and in cancer diagnosis. | 10-21-2010 |
20100287631 | WNT PATHWAY MUTATIONS IN CANCER STEM CELLS - Cancer specific splicing events in the Wnt/β-catenin signaling pathway are associated with progression of myelogenous leukemia. Misspliced genes of interest include GSK3β. In some embodiments of the invention, polynucleotides are provided that correspond to misspliced GSK3β transcripts associated with cancer. Such transcripts are characterized by a deletion of exon (8), and particularly in exon (8) and (9). Detection of such transcripts in cells is indicative of the presence of leukemia, and particularly of the presence of leukemia stem cells. In other embodiments, polypeptides are provided that are encoded by misspliced GSK3β transcripts associated with cancer. Such polypeptides are useful as diagnostic markers for cancer, and as a target for screening of therapeutic agents. Animal models comprising a human LSC having a misspliced GSK3b transcript provide a useful model for leukemia, for drug/gene screening in the prevention and treatment of leukemia in humans, etc. | 11-11-2010 |
20110014119 | Methods for Manipulating Phagocytosis Mediated by CD47 - Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc. | 01-20-2011 |
20110015090 | Markers of Acute Myeloid Leukemia Stem Cells - Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets. | 01-20-2011 |
20110076683 | Identification, Isolation and Elimination of Cancer Stem Cells - Isolated populations of leukemic stem cells are provided. The cells are useful for experimental evaluation, and as a source of lineage and cell specific products, and as targets for the discovery of factors or molecules that can affect them. Detection of leukemic stem cells is useful in predicting disease progression, relapse, and development of drug resistance. Proliferation of LSC may be inhibited through interfering with activation of the β-catenin pathway. Methods are provided for the clinical staging of pre-leukemia and leukemias by differential analysis of hematologic samples for the distribution of one or more hematopoietic stem or progenitor cell subsets. | 03-31-2011 |
20110124032 | Methods and Compositions for Treating Carcinoma Stem Cells - Cancer stem cells (CSCs) have been prospectively isolated or identified from primary tumor samples, and shown to possess the unique properties of self-renewal and differentiation, and can form unique histological microdomains useful in cancer diagnosis. Such cancer stem cells are shown herein to have the phenotype of containing decreased levels of reactive oxygen species (ROS) relative to non-tumorigenic (non-stem cell) cancer cells, as well as expression of other protective pathways. The CSCs are further shown to be more resistant to ionizing radiation (IR) and certain chemotherapies and to express high levels of ROS genes. | 05-26-2011 |
20120225073 | Isolation and Use of Melanoma Cancer Stem Cells - A set of markers for melanoma cancer stem cells are provided. The cells can be prospectively isolated or identified from primary tumor samples, and possess the unique properties of cancer stem cells in functional assays for tumor initiation, cancer stem cell self-renewal and differentiation. In addition, cancer stem cells can be used as a predictor for disease progression. The CSC have the phenotype of being positive for expression CD271. | 09-06-2012 |
20120282174 | Synergistic Anti-CD47 Therapy for Hematologic Cancers - Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2. | 11-08-2012 |
20120283124 | Cell Surface Marker Expression in Hematopoietic Stem Cells and Progenitors for the Diagnosis, Prognosis, and Treatment of Myelodysplastic Syndromes - Myelodysplastic syndromes are staged by analysis of the presence of hematopoietic stem and/or progenitor cells, particularly progenitor cells dedicated to the myeloid lineage and hematopoietic stem cells. | 11-08-2012 |
20130028909 | Depletion of Teratoma-Forming Pluripotent Stem Cells - Compositions and methods are provided for depletion of pluripotent cells. In one embodiment of the invention, methods are provided for depletion of pluripotent cells from a mixed population of differentiated cells and stem cells, to provide a population of cells substantially free of pluripotent stem cells. Monoclonal antibodies useful in depletion and in identification of pluripotent stem cells are also provided. | 01-31-2013 |
20130142786 | HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODIES TO CD47 - Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies. | 06-06-2013 |
20130209415 | PURIFIED COMPOSITIONS OF CARDIOVASCULAR PROGENITOR CELLS - Composition and methods are provided for the prospective enrichment of human cardiovascular progenitor cells, which can be differentiated into cardiomyocytes, from in vitro cultures of stem cells. The stem cells are cultured in conditions permissive for differentiation into cardiovascular progenitor cells, and cardiovascular progenitor cells are sorted for expression of one or more of the markers ROR2, CD13, KDR and PDGFαR, where the progenitor cells positively express these markers. Highly enriched populations of cardiomyocyte lineage cells can be obtained. | 08-15-2013 |
20130244326 | Markers of Acute Myeloid Leukemia Stem Cells - Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets. | 09-19-2013 |
20130281304 | Comprehensive Methylome Map of Myeloid and Lymphoid Commitment from Hematopoietic Proenitors - Provided herein are differentially methylated regions (DMRs) of multipotent progenitor cells (MPPs) and oligopotent progenitor cells and methods of use thereof. The invention provides methods for detecting and analyzing alterations in the methylation status of DMRs in such progenitor cells as well as methods for differentiating such cells. | 10-24-2013 |
20140037590 | Isolation and Characterization of Progenitor Cells From Mesothelium - Populations enriched for smooth muscle progenitors are obtained by selection on the basis of expression of specific cell surface markers. | 02-06-2014 |
20140065169 | Methods of Treating Acute Myeloid Leukemia by Blocking CD47 - Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc. | 03-06-2014 |
20140161805 | Methods for Manipulating Phagocytosis Mediated by CD47 - Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable. | 06-12-2014 |
20140161825 | Methods of Treating Acute Myeloid Leukemia by Blocking CD47 - Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc. | 06-12-2014 |
20140255431 | Markers of Acute Myeloid Leukemia Stem Cells - Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets. | 09-11-2014 |
20140271683 | Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor - Therapeutic and diagnostic methods are provided, which methods relate to the expression of calreticulin on cancer cells and hematopoietic cells. | 09-18-2014 |
20140369924 | SYNERGISTIC ANTI-CD47 THERAPY FOR HEMATOLOGIC CANCERS - Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2. | 12-18-2014 |
20150071905 | High Affinity Sirp-Alpha Reagents - High affinity SIRP-α reagent are provided, which (i) comprise at least one amino acid change relative to the wild-type protein; and (ii) have an increased affinity for CD47 relative to the wild-type protein. Compositions and methods are provided for modulating phagocytosis in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity SIRPα reagent, which blocks the physiological binding interaction between SIRPα and its ligand CD47. | 03-12-2015 |